**Table S2.Tissue-specific KGB-1 activation shortens lifespan. All experiments**

|  |  |  |  |
| --- | --- | --- | --- |
| **Strain** | **TD50a (days)** | **N** | **p-valueb** |
|  | **EV** | **vhp-1** | **EV** | **vhp-1** |  |
| N2 | 18.13 | 15.33 | 114 | 117 | \*\*\* |
|  | 26.50 | 17.14 | 122 | 104 | \*\*\* |
| *kgb-1(km21)* | 13.88 | 17.07 | 111 | 111 | n.s. |
|  | 17.13 | 17.75 | 98 | 110 | n.s. |
| Neuronal *kgb-1* | 14.67 | 10.57 | 86 | 116 | \*\*\* |
|  | 23.67 | 15.05 | 80 | 57 | \*\*\* |
| Muscle *kgb-1* | 14.67 | 10.43 | 116 | 89 | \*\*\* |
|  | 13.42 | 11.88 | 130 | 67 | \*\* |
| Intestinal *kgb-1* | 26.00 | 18.80 | 87 | 99 | \* |
|  | 24.75 | 17.44 | 78 | 130 | \*\*\* |
| Epidermal *kgb-1* | 13.78 | 15.98 | 69 | 103 | n.s. |
|  | 14.94 | 15.91 | 100 | 100 | n.s. |

a TD50 was calculated using Kaplan-Meier analysis.

b Asterisks represent significant differences in survival curves upon *vhp-1* knockdown compared to EV controls (\*p<0.05, \*\*p<0.01, \*\*\*p<0.0001).